HBIO
Harvard Bioscience, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$8.02
+0.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 87.8M | 86.5M | 94.1M | 112.3M | 113.3M |
| Cost of Revenue | 36.7M | 40.7M | 39.4M | 46.2M | 52.5M |
| Gross Profit | 51.1M | 45.9M | 54.8M | 66.1M | 60.8M |
| Operating Expenses | |||||
| R&D Expense | 9.1M | 8.8M | 10.4M | 11.8M | 12.3M |
| SG&A Expense | 38.1M | 37.0M | 43.7M | 46.9M | 49.5M |
| General & Admin Expense | 17.6M | 17.7M | 21.5M | 22.8M | 24.5M |
| Selling & Marketing Expense | 20.4M | 19.2M | 22.2M | 24.1M | 25.0M |
| Other Expenses | 2.9M | 729.0K | 6.9M | 5.5M | 5.9M |
| Total Operating Expenses | 50.0M | 46.5M | 61.0M | 64.2M | 67.8M |
| Cost and Expenses | 86.8M | 87.2M | 100.3M | 110.4M | 120.3M |
| Operating Income (EBIT) | 1.0M | (629.0K) | (6.2M) | 1.9M | (6.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 3.4M | 4.9M | 3.2M | 3.6M | 2.5M |
| Net Interest Income | (3.4M) | (4.9M) | (3.2M) | (3.6M) | (2.5M) |
| Other Non-Op Income/Expense | (11.6M) | (56.8M) | (5.5M) | (4.5M) | (2.2M) |
| Non-Operating Income (excl Interest) | 8.2M | 51.8M | 2.2M | 859.0K | (302.0K) |
| EBT (Pre-Tax Income) | (10.5M) | (57.4M) | (11.7M) | (2.6M) | (9.2M) |
| Income Tax Expense | (129.0K) | (686.0K) | 740.0K | 859.0K | 337.0K |
| Bottom Line | |||||
| Net Income | (10.4M) | (56.7M) | (12.4M) | (3.4M) | (9.5M) |
| Earnings from Cont. Ops | (10.4M) | (56.7M) | (12.4M) | (3.4M) | (9.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.4M) | (56.7M) | (12.4M) | (3.4M) | (9.5M) |
| Per Share | |||||
| Basic EPS | ($2.33) | ($12.80) | ($2.80) | ($0.81) | ($2.30) |
| Diluted EPS | ($2.33) | ($12.80) | ($2.80) | ($0.81) | ($2.30) |
| Revenue Per Share | $19.40 | $19.50 | $21.62 | $26.46 | $27.37 |
| Shares | |||||
| Basic Shares Outstanding | 4.5M | 4.4M | 4.4M | 4.2M | 4.1M |
| Diluted Shares Outstanding | 4.5M | 4.4M | 4.4M | 4.2M | 4.1M |
| Profitability Metrics | |||||
| EBITDA | (939.0K) | (46.5M) | (1.5M) | 8.0M | 944.0K |
| D&A | 6.2M | 5.9M | 7.0M | 7.0M | 7.6M |
| EBIT | (7.2M) | (52.5M) | (8.5M) | 1.0M | (6.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026